002262 恩华药业
已收盘 09-11 15:00:00
资讯
新帖
简况
国药控股与恩华药业签署新一轮战略合作协议
同花顺 · 09-10 17:40
国药控股与恩华药业签署新一轮战略合作协议
股市必读：恩华药业（002262）9月3日董秘有最新回复
证券之星 · 09-04
股市必读：恩华药业（002262）9月3日董秘有最新回复
恩华药业：公司销售模式是采用赊销方式
证券之星 · 09-03
恩华药业：公司销售模式是采用赊销方式
股市必读：恩华药业新发布《关于部分限制性股票回购注销完成的公告（1）》
证券之星 · 08-28
股市必读：恩华药业新发布《关于部分限制性股票回购注销完成的公告（1）》
恩华药业（002262）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-19
恩华药业（002262）2026年中报简析：营收净利润同比双双增长
恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%
证券之星 · 08-18
恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%
恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验
美股速递 · 08-18
恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验
恩华药业(002262.SZ)：1类创新药NH302注射液获批开展临床试验
智通财经 · 08-18
恩华药业(002262.SZ)：1类创新药NH302注射液获批开展临床试验
图解恩华药业中报：第二季度单季净利润同比增长5.87%
证券之星 · 08-18
图解恩华药业中报：第二季度单季净利润同比增长5.87%
恩华药业（002262）披露2026年半年度报告，8月17日股价下跌1.32%
证券之星 · 08-17
恩华药业（002262）披露2026年半年度报告，8月17日股价下跌1.32%
股市必读：恩华药业（002262）8月4日董秘有最新回复
证券之星 · 08-05
股市必读：恩华药业（002262）8月4日董秘有最新回复
恩华药业：NH600001处于正常审核之中
证券之星 · 08-04
恩华药业：NH600001处于正常审核之中
恩华药业：公司创新药NH600001处于CDE正常审核之中
证券之星 · 07-22
恩华药业：公司创新药NH600001处于CDE正常审核之中
恩华药业获得发明专利授权：“(R)-3-[(苯并二氧戊环-4-基)氧基]-N,N-二甲基-3-(4-氟苯基)丙胺草酸盐的晶型及其制备方法和应用”
证券之星 · 07-15
恩华药业获得发明专利授权：“(R)-3-[(苯并二氧戊环-4-基)氧基]-N,N-二甲基-3-(4-氟苯基)丙胺草酸盐的晶型及其制备方法和应用”
股市必读：恩华药业（002262）7月8日董秘有最新回复
证券之星 · 07-09
股市必读：恩华药业（002262）7月8日董秘有最新回复
恩华药业：公司创新药NH600001乳状注射液目前处于CDE正常审核之中
证券之星 · 07-06
恩华药业：公司创新药NH600001乳状注射液目前处于CDE正常审核之中
恩华药业（002262）披露回购注销部分限制性股票减资暨通知债权人公告，6月30日股价下跌3.1%
证券之星 · 06-30
恩华药业（002262）披露回购注销部分限制性股票减资暨通知债权人公告，6月30日股价下跌3.1%
恩华药业：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售
证券之星 · 06-30
恩华药业：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售
股市必读：恩华药业（002262）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：恩华药业（002262）6月18日董秘有最新回复
恩华药业：公司一类创新药NH600001的审批进展一切正常顺利
证券之星 · 06-18
恩华药业：公司一类创新药NH600001的审批进展一切正常顺利
加载更多
公司概况
公司名称：
江苏恩华药业股份有限公司
所属行业：
医药制造业
上市日期：
2008-07-23
主营业务：
江苏恩华药业股份有限公司的主营业务是医药研发、生产和销售。公司的主要产品是原料药、麻醉类制剂、精神类制剂、神经类制剂。公司荣获“2026年度资信等级AAA”、“2026中国医药创新企业100强”、“2026化药研发实力20强”、“2026药品研发综合实力50强”等荣誉，恩华络康被纳入火炬企业库，恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。
发行价格：
5.68
{"stockData":{"symbol":"002262","market":"SZ","secType":"STK","nameCN":"恩华药业","latestPrice":21.44,"timestamp":1789110189000,"preClose":21.85,"halted":0,"volume":7361533,"delay":0,"changeRate":-0.0188,"floatShares":884000000,"shares":1013000000,"eps":1.0835,"marketStatus":"已收盘","change":-0.41,"latestTime":"09-11 15:00:00","open":21.72,"high":21.98,"low":21.41,"amount":158000000,"amplitude":0.0261,"askPrice":21.44,"askSize":51,"bidPrice":21.43,"bidSize":32,"shortable":0,"etf":0,"ttmEps":1.0835,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":21.85,"symbolType":"stock","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":24.04,"lowLimit":19.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1012971423,"isCdr":false,"pbRate":2.64,"roa":"--","peRate":19.787725,"roe":"8.86%","epsLYR":1.05,"committee":0.496435,"marketValue":21718000000,"turnoverRate":0.0083,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","floatMarketCap":18948000000},"requestUrl":"/m/hq/s/002262","defaultTab":"news","newsList":[{"id":"2666556434","title":"国药控股与恩华药业签署新一轮战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2666556434","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666556434?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:40","pubTimestamp":1789033200,"startTime":"0","endTime":"0","summary":"近日，国药控股与恩华药业在上海举行战略合作沟通会，双方以“同行致远 共赴新程”为主题，围绕准入协同、商销一体化、零售终端等方向深入交流，并签署新一轮战略合作协议。国药控股党委副 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260910/c679790430.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260910/c679790430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1064131003.USD","LU1064130708.USD","BK0070","BK0188","BK0239","LU2148510915.USD","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664806846","title":"股市必读：恩华药业（002262）9月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664806846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664806846?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:44","pubTimestamp":1788457455,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，恩华药业报收于22.6元，上涨0.44%，换手率0.63%，成交量5.59万手，成交额1.26亿元。董秘最新回复投资者： 董秘好，我想了解下公司应收账款占比这么高，请问公司销售模式是赊销方式吗？账期都是多长时间？客户性质不同，账期有所不同。当日关注点交易信息汇总：9月3日主力资金净流入328.04万元，占总成交额2.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU1064131003.USD","002262","BK0070","LU2148510915.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820046","title":"恩华药业：公司销售模式是采用赊销方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664820046?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:54","pubTimestamp":1788425648,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)09月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，我想了解下公司应收账款占比这么高，请问公司销售模式是赊销方式吗？账期都是多长时间？恩华药业回复：公司应收账款的销售占比与同类公司同口径比较而言基本相当，反映了公司所处行业的销售回款现状。目前，公司销售模式是采用赊销方式。客户性质不同，账期有所不同。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300030395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","LU2148510915.USD","BK0188","LU1064131003.USD","LU1064130708.USD","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662803820","title":"股市必读：恩华药业新发布《关于部分限制性股票回购注销完成的公告（1）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662803820","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662803820?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:14","pubTimestamp":1787861653,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，恩华药业报收于22.02元，下跌0.5%，换手率0.8%，成交量7.07万手，成交额1.55亿元。当日关注点交易信息汇总：8月27日主力资金净流出616.57万元，占总成交额3.98%。公司公告汇总：恩华药业完成281.5160万股限制性股票回购注销，总股本由101,578.6583万股减至101,297.1423万股。回购价格为10.75元/股，回购原因为部分激励对象离职或退休，以及公司2025年度业绩未达股权激励计划第二个解除限售期的考核目标。本次回购注销不影响公司经营成果和股权分布上市条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0188","002262","LU2148510915.USD","LU1064131003.USD","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660859490","title":"恩华药业（002262）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2660859490","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660859490?lang=zh_cn&edition=full","pubTime":"2026-08-19 06:08","pubTimestamp":1787090887,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩华药业发布2026年中报。根据财报显示，恩华药业营收净利润同比双双增长。截至本报告期末，公司营业总收入32.18亿元，同比上升6.91%，归母净利润7.41亿元，同比上升5.74%。持有恩华药业最多的基金为华夏复兴混合A，目前规模为15.71亿元，最新净值2.816，较上一交易日上涨0.43%，近一年上涨24.88%。本文数据来源于恩华药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900004076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465980","title":"恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465980","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660465980?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:28","pubTimestamp":1787045328,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩华药业披露，截至2026年6月30日公司股东户数为5.34万户，较3月31日增加1.03万户，增幅为23.8%。在化学制药行业个股中，恩华药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.64万户。从股价来看，2026年3月31日至2026年6月30日，恩华药业区间跌幅为14.61%，在此期间股东户数增加1.03万户，增幅为23.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002262","LU1064131003.USD","LU2148510915.USD","BK0070","LU1064130708.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194623670","title":"恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1194623670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194623670?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:57","pubTimestamp":1787025428,"startTime":"0","endTime":"0","summary":"恩华药业宣布，其自主研发的NH302注射液与NH130枸橼酸盐片已获得国家药品监督管理局（NMPA）的临床试验批准。这一进展标志着公司在创新药物研发领域迈出了关键一步。两项药物均处于临床开发早期阶段，未来将针对特定适应症展开系统评估。此次获批不仅凸显了恩华药业在神经精神类药物领域的持续深耕，也为后续产品管线推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0188","LU1064131003.USD","LU2148510915.USD","BK0239","002262","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660459730","title":"恩华药业(002262.SZ)：1类创新药NH302注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660459730","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660459730?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:55","pubTimestamp":1787025354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的1类化学药品NH302注射液的《药物临床试验批准通知书》，并将于近期开展临床试验。NH302为外周选择性Kappa受体激动剂。临床前试验结果表明：NH302对Kappa受体具有较强的激动活性，对多个疼痛动物模型均具有较好的镇痛效果，起效剂量低，作用时间长，镇静安全窗大，有望开发为具备明显临床优势的急性疼痛治疗药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","BK0239","BK0188","BK1574","BMED","IBBQ","LU2148510915.USD","MDTX","MEDX","LNGR","159992","BK1161","LU1064130708.USD","002262","PSYK","LU1064131003.USD","BK0070","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431341","title":"图解恩华药业中报：第二季度单季净利润同比增长5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431341","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431341?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:25","pubTimestamp":1786987526,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业2026年中报显示，上半年度公司主营收入32.18亿元，同比上升6.91%；归母净利润7.41亿元，同比上升5.74%；扣非净利润7.46亿元，同比上升6.65%；其中2026年第二季度，公司单季度主营收入16.08亿元，同比上升7.25%；单季度归母净利润4.23亿元，同比上升5.87%；单季度扣非净利润4.28亿元，同比上升7.03%；负债率12.3%，投资收益3591.47万元，财务费用-564.84万元，毛利率73.86%。财报数据概要请见下图:本文数据来源于恩华药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660435999","title":"恩华药业（002262）披露2026年半年度报告，8月17日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435999","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660435999?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:34","pubTimestamp":1786977261,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，恩华药业报收于21.67元，较前一交易日下跌1.32%，最新总市值为220.12亿元。该股当日开盘22.08元，最高22.08元，最低21.44元，成交额达2.03亿元，换手率为1.06%。近日，恩华药业披露《2026年半年度报告》。报告显示，本报告期营业收入为3,218,250,058.44元，同比增长6.91%；归属于上市公司股东的净利润为740,682,973.24元，同比增长5.74%；扣除非经常性损益后的净利润为745,987,159.61元，同比增长6.65%。经营活动产生的现金流量净额为280,408,381.42元，同比下降43.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700035816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0239","BK0070","002262","LU2148510915.USD","BK0188","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657379563","title":"股市必读：恩华药业（002262）8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657379563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657379563?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:39","pubTimestamp":1785865150,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，恩华药业报收于21.91元，下跌1.44%，换手率1.15%，成交量10.21万手，成交额2.25亿元。董秘最新回复投资者： 请问董秘，NH600001发补完成了吗？董秘： 公司NH600001处于正常审核之中，相关工作在有序顺利推进。获得该创新药上市批件后，公司会及时进行公告。当日关注点交易信息汇总：8月4日主力资金净流入684.21万元，占总成交额3.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002262","LU1064131003.USD","LU2148510915.USD","BK0070","LU1064130708.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656362025","title":"恩华药业：NH600001处于正常审核之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2656362025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656362025?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:45","pubTimestamp":1785833114,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，NH600001发补完成了吗？恩华药业回复：公司NH600001处于正常审核之中，相关工作在有序顺利推进。获得该创新药上市批件后，公司会及时进行公告。请关注公司公告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400027790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU1064131003.USD","BK0239","LU1064130708.USD","LU2148510915.USD","002262","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653816753","title":"恩华药业：公司创新药NH600001处于CDE正常审核之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2653816753","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653816753?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:33","pubTimestamp":1784709195,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业07月22日在投资者关系平台上答复投资者关心的问题。今天是7月21日，新药NH600001在6月8日六灯全灭的，到现在第30个工作日了，据说CDE结尾审批超过30个工作日属于重度超时。麻烦问一下，1、NH600001CDE审批环节是否一切顺利，有没有可能重度超时。恩华药业回复：公司创新药NH600001处于CDE正常审核之中，各项相关工作在有序顺利进行。获得该创新药上市批件后，公司会及时进行公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200033623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU1064131003.USD","06978","BK0239","BK0070","002262","LU2148510915.USD","BK1161","LU1064130708.USD","BK0188","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651545486","title":"恩华药业获得发明专利授权：“(R)-3-[(苯并二氧戊环-4-基)氧基]-N,N-二甲基-3-(4-氟苯基)丙胺草酸盐的晶型及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651545486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651545486?lang=zh_cn&edition=full","pubTime":"2026-07-15 03:28","pubTimestamp":1784057294,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示恩华药业新获得一项发明专利授权，专利名为“-3-[氧基]-N,N-二甲基-3-丙胺草酸盐的晶型及其制备方法和应用”，专利申请号为CN202411527154.6，授权日为2026年7月14日。专利摘要：本发明涉及化合物3[氧基]N,N二甲基3丙胺草酸盐、晶型及其制备方法和应用和含有治疗有效量的该化合物的盐、晶型的药物组合物，及其在制备预防和/或治疗精神类疾病药物中的用途。今年以来恩华药业新获得专利授权14个，较去年同期增加了16.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500005319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","LU1064131003.USD","BK0239","LU1064130708.USD","BK0070","LU2148510915.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650900809","title":"股市必读：恩华药业（002262）7月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2650900809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650900809?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:26","pubTimestamp":1783531568,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，恩华药业报收于19.62元，下跌0.76%，换手率0.97%，成交量8.57万手，成交额1.69亿元。董秘最新回复投资者： 截止6月30日股东人数多少？由于“互动易”平台不属于公司信息的法定披露渠道，为严格遵守信息披露公平性原则，保障全体投资者信息获取一致，公司会在定期报告中披露股东人数和前十大股东持股情况。交易信息汇总资金流向7月8日主力资金净流出924.69万元；游资资金净流出534.72万元；散户资金净流入1459.41万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002262","BK0188","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649232416","title":"恩华药业：公司创新药NH600001乳状注射液目前处于CDE正常审核之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2649232416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649232416?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:27","pubTimestamp":1783333635,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业07月06日在投资者关系平台上答复投资者关心的问题。恩华药业回复：公司创新药NH600001乳状注射液目前处于CDE正常审核之中，各项相关工作进展顺利，力争早日获批上市。获得该创新药批件后，公司会及时进行公告。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600029471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002262","BK0070","BK1161","LU1064130708.USD","BK1574","BK0188","159992","LU2148510915.USD","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647552948","title":"恩华药业（002262）披露回购注销部分限制性股票减资暨通知债权人公告，6月30日股价下跌3.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647552948","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647552948?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:20","pubTimestamp":1782829236,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，恩华药业报收于18.75元，较前一交易日下跌3.1%，最新总市值为190.46亿元。近日，江苏恩华药业股份有限公司发布《关于回购注销部分限制性股票减资暨通知债权人的公告》。公告显示，公司于2026年6月12日召开第七届董事会第八次会议，审议通过《关于回购注销部分限制性股票的议案》。本次回购注销完成后，公司注册资本将由101,578.6583万元减少至101,297.1423万元。债权人自公告披露之日起45日内可要求公司清偿债务或提供担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000047096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","LU1064131003.USD","LU2148510915.USD","BK0239","002262","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647536285","title":"恩华药业：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2647536285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647536285?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:51","pubTimestamp":1782809477,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司目前在越南有哪些产品已经获批上市或实现销售？销售量是多少？恩华药业回复：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0239","BK0070","LU1064131003.USD","FVNmain","BK0188","LU2148510915.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645016200","title":"股市必读：恩华药业（002262）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645016200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645016200?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:09","pubTimestamp":1782076154,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，恩华药业报收于18.69元，下跌0.11%，换手率1.13%，成交量9.96万手，成交额1.87亿元。董秘最新回复投资者： 尊敬的董秘，网传公司创新药发补要拖到明年了，是否属实？董秘： 公司一类创新药NH600001的审批进展一切正常顺利！有关公司新药开发的重要信息一切以公司公告为准。当日关注点交易信息汇总：6月18日主力资金净流出125.51万元，游资资金净流出118.27万元，散户资金净流入243.78万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","LU1064130708.USD","LU2148510915.USD","BK0188","BK0239","BK0070","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644830771","title":"恩华药业：公司一类创新药NH600001的审批进展一切正常顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2644830771","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644830771?lang=zh_cn&edition=full","pubTime":"2026-06-18 11:54","pubTimestamp":1781754843,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，网传公司创新药发补要拖到明年了，是否属实？谢谢！恩华药业回复：公司一类创新药NH600001的审批进展一切正常顺利！有关公司新药开发的重要信息一切以公司公告为准。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800018446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0188","06978","002262","159992","LU2148510915.USD","BK1161","BK0070","LU1064131003.USD","BK0239","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789267567128,"stockEarnings":[{"period":"1week","weight":-0.0496},{"period":"1month","weight":-0.0299},{"period":"3month","weight":0.1029},{"period":"6month","weight":-0.031},{"period":"1year","weight":-0.1643},{"period":"ytd","weight":-0.0936}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恩华药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"53378人(较上一季度增加23.80%)","perCapita":"16556股","listingDate":"2008-07-23","address":"江苏省徐州市鼓楼区经济技术开发区杨山路18号","registeredCapital":"101297万元","survey":" 江苏恩华药业股份有限公司的主营业务是医药研发、生产和销售。公司的主要产品是原料药、麻醉类制剂、精神类制剂、神经类制剂。公司荣获“2026年度资信等级AAA”、“2026中国医药创新企业100强”、“2026化药研发实力20强”、“2026药品研发综合实力50强”等荣誉，恩华络康被纳入火炬企业库，恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。","listedPrice":5.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩华药业,002262,恩华药业股票,恩华药业股票老虎,恩华药业股票老虎国际,恩华药业行情,恩华药业股票行情,恩华药业股价,恩华药业股市,恩华药业股票价格,恩华药业股票交易,恩华药业股票购买,恩华药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}